Case reports show prenatal treatment of cystic fibrosis may reduce meconium ileous in affected fetuses, indicating potential benefits for lung and pancreatic function.
Key Points
Improved quality of life observed in cystic fibrosis patients receiving prenatal therapy, reducing complications.
Two cases report prenatal use of CFTR therapy to prevent meconium ileous, highlighting clinical implications.
Amniocentesis confirmed cystic fibrosis diagnosis in both cases, ensuring accurate treatment strategies were applied.
Ethical concerns arise from compassionate use of CFTR therapy in pregnant women without formal approval for newborns.